Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma.
Pseudoexfoliation (PEX) syndrome, which is an age-related, generalized elastotic matrix process, currently represents the most common identifiable risk factor for open-angle glaucoma. Dysregulated expression of proinflammatory cytokines has been implicated in the initiation of various fibrotic disorders and in the pathophysiology of glaucoma. Here we investigated the presence, expression, regulation, and functional significance of proinflammatory cytokines in eyes with early and late stages of PEX syndrome/glaucoma in comparison with normal and glaucomatous control eyes using multiplex bead analysis, immunoassays, real-time PCR, Western blotting, immunohistochemistry, and cell culture models. Early stages of PEX syndrome were characterized by approximately threefold (P < 0.005) elevated interleukin (IL)-6 and IL-8 levels in the aqueous humor and a concomitant approximately twofold (P < 0.001) increase in mRNA expression levels in anterior segment tissues as compared with controls. In contrast, late stages of PEX syndrome/glaucoma did not differ significantly from controls. IL-6, IL-6 receptor, and phospho-signal transducer and activator of transcription 3 could be mainly localized to walls of iris vessels and to the nonpigmented epithelium of ciliary processes. IL-6 and IL-8 were significantly up-regulated by ciliary epithelial cells in response to hypoxia or oxidative stress in vitro, whereas IL-6, but not IL-8, induced the expression of transforming growth factor-beta1 and elastic fiber proteins. These findings support a role for a stress-induced, spatially, and temporally restricted subclinical inflammation in the onset of the fibrotic matrix process characteristic of PEX syndrome/glaucoma.
Zenkel
Matthias
M
Department of Ophthalmology, University of Erlangen-Nürnberg, Schwabachanlage 6, D-91054 Erlangen, Germany. matthias.zenkel@uk-erlangen.de
Lewczuk
Piotr
P
Jünemann
Anselm
A
Kruse
Friedrich E
FE
Naumann
Gottfried O H
GO
Schlötzer-Schrehardt
Ursula
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001082:Aqueous Humor / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000235:genetics / Q000276:immunology*; D017889:Exfoliation Syndrome / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D005109:Extracellular Matrix / Q000378:metabolism / Q000473:pathology*; D005123:Eye / Q000033:anatomy & histology / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005902:Glaucoma, Open-Angle / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000276:immunology; D016209:Interleukin-8 / Q000235:genetics / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data
D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8
J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):575-84
16799139
Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1447-57
17389470
Am J Ophthalmol. 2006 May;141(5):921-937
16678509
Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):572-81
16677101
Respir Res. 2002;3:1
11806836
Br J Ophthalmol. 2003 Mar;87(3):353-6
12598453
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4251-9
16249505
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10061-5
7694279
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):352-61
10670462
Br J Dermatol. 2009 Aug;161(2):237-48
19438433
Hepatology. 2006 Dec;44(6):1487-501
17133487
Ophthalmic Res. 1995;27 Suppl 1:136-42
8577452
Rev Esp Enferm Dig. 2005 Aug;97(8):575-95
16266225
Exp Eye Res. 2001 Dec;73(6):765-80
11846508
Am J Ophthalmol. 2006 Jul;142(1):192-4
16815285
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2796-801
19182256
Clin Immunol Immunopathol. 1992 Dec;65(3):278-85
1451330
J Clin Invest. 2001 Jun;107(12):1529-36
11413160
Endocrinology. 1992 Aug;131(2):710-4
1639018
Am J Pathol. 2008 Dec;173(6):1724-35
18974306
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5558-66
18055805
Stem Cells. 1994 May;12(3):262-77
8075593
Invest Ophthalmol Vis Sci. 2002 May;43(5):1475-87
11980863
J Invest Dermatol. 1991 Oct;97(4):686-92
1940439
Connect Tissue Res. 2007;48(5):263-70
17882702
Prog Retin Eye Res. 2004 Jul;23(4):435-48
15219876
J Rheumatol. 1998 Feb;25(2):308-13
9489824
Science. 2007 Sep 7;317(5843):1397-400
17690259
J Clin Invest. 2001 Jun;107(12):1501-2
11413155
J Cell Physiol. 1989 Nov;141(2):243-52
2553750
Invest Ophthalmol Vis Sci. 2007 May;48(5):2203-7
17460280
Nat Med. 2001 Mar;7(3):304-9
11231628
Arch Ophthalmol. 2001 Jul;119(7):1023-31
11448324
Arch Ophthalmol. 1987 Aug;105(8):1076-82
3632416
Biochem Biophys Res Commun. 2005 Dec 2;337(4):1229-36
16229816
Invest Ophthalmol Vis Sci. 2006 May;47(5):1982-90
16639006
J Glaucoma. 2008 Aug;17(5):378-85
18703948
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2627-32
10509659
Surv Ophthalmol. 2001 Jan-Feb;45(4):265-315
11166342
Cornea. 1997 Sep;16(5):580-7
9294693
Cytokine. 2000 Jun;12(6):671-6
10843743
Ger J Ophthalmol. 1994 May;3(3):148-53
8038683
Arch Dermatol Res. 2003 Jan;294(10-11):433-7
12563540
Mol Vis. 2009;15:326-34
19209241
J Ocul Biol Dis Infor. 2009 Jun;2(2):78-83
19672464
Mol Vis. 2007 Dec 17;13:2282-8
18199969
Am J Respir Cell Mol Biol. 1998 Oct;19(4):653-61
9761763